πŸ‡ΊπŸ‡Έ FDA
Patent

US 11033570

Modulation of Lnc05 expression

granted A61KA61K31/7125A61K31/713

Quick answer

US patent 11033570 (Modulation of Lnc05 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/7125, A61K31/713, A61K45/06, A61K9/0019